<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97615">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116257</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0702</org_study_id>
    <nct_id>NCT02116257</nct_id>
  </id_info>
  <brief_title>The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While Patient-controlled analgesia (PCA) has the advantage of effectively reducing the
      degree of postoperative pain, it can also affect the patient's outcome by several adverse
      effects such as postoperative nausea and vomiting (PONV). Especially for high risk group of
      patients for PONV, the ideal regimen for sufficient analgesia with minimal adverse effect
      needs to be sought. Propacetamol is known for its effective, rapid analgesia, opioid-sparing
      effect, and is used widely for post operative pain management. This study aims to see the
      opioid-sparing effect and the degree of PONV when propacetamol is added to PCA for high risk
      PONV patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>PCA drug consumption</measure>
    <time_frame>48 hours after the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>amount of residual PCA drug are measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of postoperation pain</measure>
    <time_frame>48 hours after the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Degree of pain at both resting and movement according to 0-100 mm visual analogue scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Severity and incidence of nausea</measure>
    <time_frame>48 hours after the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Degree of nausea, vomiting according to 0-10 visual numerical rating scale. Number of nausea, vomiting events.</description>
  </other_outcome>
  <other_outcome>
    <measure>vomiting</measure>
    <time_frame>48 hours after the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Degree of nausea, vomiting according to 0-10 visual numerical rating scale. Number of nausea, vomiting events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>PONV</condition>
  <condition>Propacetamol</condition>
  <arm_group>
    <arm_group_label>Propacetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA regimen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>routine PCA drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propacetamol</intervention_name>
    <description>total 2g of Propacetamol added to patient's PCA regimen</description>
    <arm_group_label>Propacetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCA regimen</intervention_name>
    <arm_group_label>PCA regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients scheduled for either 1-2 level spine fusion or laminectomy

          2. ASA (American Society of Anesthesiology) physical status 1 or 2

          3. Non-smoking female patients, between the age 20 and 65

        Exclusion Criteria:

          1. Administration of any anti-emetic agents within 24 hours prior to surgery

          2. Administration of any opioid agents within 7 days prior to surgery

          3. Regular administration of any steroid agents

          4. Drug or alcohol-abuser

          5. Patients with bowel movement disorder, liver or renal impairment, insulin-dependent
             diabetes. Patients who are pregnant, illiterate, or foreign.

          6. Patients administered to Intensive Care Unit after surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jong-Wook Song, MD</last_name>
    <phone>+82-2-2227-3971</phone>
    <email>sjw72331@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Wook Song, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>April 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propacetamol</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
